Clinical value of atezolizumab plus bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.

被引：0
|
作者：
Vogel, Arndt
Rimassa, Lorenza
Sun, Hui-Chuan
Abou-Alfa, Ghassan K.
El-Khoueiry, Anthony B.
Pinato, David James
Daigl, Monica
Alvarez, Javier Sanchez
Orfanos, Panos
Leibfried, Michael
Zumofen, Marie-Helene Blanchet
Gaillard, Vincent
Merle, Philippe
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Humanitas Univ, Pieve Emanuele, Italy
[3] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Weill Cornell Med Coll, New York, NY USA
[6] USC Norris Comprehens Canc Ctr, Keck Sch Med, Div Med Oncol, Los Angeles, CA USA
[7] Imperial Coll London, Dept Surg & Canc, London, England
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Hop Croix Rousse, Dept Hepatol, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4585
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta-analysis
    Zhu, Gang
    Zeng, Longfei
    Yang, Liu
    Zhang, Xin
    Tang, Jinquan
    Pan, Yong
    Li, Bo
    Chen, Mengchen
    Wu, Tao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (10) : 1425 - 1434
  • [2] Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
    Mohri, Kunihide
    Nagai, Hidenari
    Matsuda, Takahisa
    Igarashi, Yoshinori
    Higai, Koji
    ANTICANCER RESEARCH, 2024, 44 (09) : 3919 - 3929
  • [3] Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
    Hou, Yanli
    Wu, Bin
    CANCER COMMUNICATIONS, 2020, 40 (12) : 743 - 745
  • [4] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
    Wang, Bi-Cheng
    Kuang, Bo-Hua
    Lin, Guo-He
    TARGETED ONCOLOGY, 2024, 19 (02) : 203 - 212
  • [5] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
    Bi-Cheng Wang
    Bo-Hua Kuang
    Guo-He Lin
    Targeted Oncology, 2024, 19 : 203 - 212
  • [6] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    JAMA NETWORK OPEN, 2021, 4 (02)
  • [7] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Mulla, Sohail
    Wang, Yulei
    Lim, Ho Yeong
    Zhu, Andrew X.
    Cheng, Ann-Lii
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20): : 1894 - 1905
  • [8] Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
    Lee, Kyung-Hun
    Lee, Michael S.
    LANCET ONCOLOGY, 2020, 21 (09): : E413 - E413
  • [9] Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Chen, Xiaoyu
    CANCER, 2022, 128 (22) : 3995 - 4003
  • [10] BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
    Amadeo, E.
    Persano, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Yoo, C.
    Rossari, F.
    Vitiello, F.
    Gardini, A. Casadei
    Rimini, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1539 - S1540
12345